摘要
目的探讨痰热清联合胸腺肽治疗脑卒中合并肺炎的临床效果及安全性。方法选择广东省湛江中心人民医院2012年8月～2013年12月收治的136例脑卒中（表热证）合并肺炎患者,采用随机数字表法将其分为治疗组和对照组,各68例。在西医常规治疗的基础上,治疗组加用痰热清联合胸腺肽治疗,对照组加用痰热清治疗。通过对退热时间、咳嗽和咯痰缓解时间、啰音消失时间、X线片影消失时间、白细胞恢复时间、住院时间等观察指标及不良反应进行比较,对两组临床疗效进行评价。结果治疗组退热时间、咳嗽和咯痰缓解时间、啰音消失时间、X线片影消失时间、白细胞恢复时间、住院时间均短于对照组,差异有统计学意义（P〈0.05）。治疗组有效率为97.06%,对照组有效率为85.29%,差异有统计学意义（P〈0.05）。治疗组不良反应发生率为8.82%,对照组为10.29%,差异有统计学意义（P〈0.05）。结论痰热清联合胸腺肽治疗脑卒中合并肺炎具有较好的效果,不良反应较少,安全性好,值得临床推广应用。
Objective To discuss the clinical efficacy and safety of Tanreqing Injection combined with thymosin in treatment of stroke associated pneumonia. Methods 136 cases of patients with stroke（exterior heat syndrome） associated pneumonia admitted to the Central People＇s Hospital of Zhanjiang City from August 2012 to December 2013 were chosen and randomly divided into the treatment group and the control group, with 68 cases in each group. Besides the routine treatment of western medicine, the treatment group was also added Tanreqing Injection combined with thymosin into the treatment, while the control group used Tanreqing Injection only. By comparing the observation targets such as fever, cough and expectoration remission time, rales disappearance time and X-ray shadow disappearance time, white blood cell recovery time, hospitalization time and consequently generating adverse reactions, the clinical efficacy of the two groups was evaluated. Results The abatement time of fever, cough and expectoration remission time and hospitalization time were shorter than the control group, the differences were statistically significant（P〈0.05）; the effective rate of the treatment group was 97.06%, which was higher than that of the control group（85.29%）, the difference was statistically significant（P〈0.05）; incidence of adverse reaction of treatment group was 10.29%, which was 8.82% in the control group, the difference was statistically significant（P〈0.05）. Conclusion Tanreqing Injection combined with thymosin is worthy of clinical application because of its better therapeutic effect, fewer adverse reaction and higher security in treating stroke associated pneumonia.
出处
《中国医药导报》
CAS
2014年第21期60-63,共4页
China Medical Herald
基金
广东省湛江市第一批非资助科技攻关计划项目(编号2013B01024)
关键词
脑卒中
肺炎
痰热清
胸腺肽
疗效
不良反应
Stroke
Pneumonia
Tanreqing
Thymosin
Efficacy
Adverse reaction
作者简介
郑小清（1965．8-），女，副主任药师，研究方向：医院药学。
